In the BioHarmony Drug Report Database

"Preview" Icon

Lisdexamfetamine

Vyvanse (lisdexamfetamine) is a small molecule pharmaceutical. Lisdexamfetamine was first approved as Vyvanse on 2007-02-23. It is used to treat attention deficit disorder with hyperactivity and binge drinking in the USA. Vyvanse’s patent is valid until 2023-02-24 (FDA).

 

Trade Name

 

Vyvanse
 

Common Name

 

lisdexamfetamine
 

ChEMBL ID

 

CHEMBL1201222
 

Indication

 

attention deficit disorder with hyperactivity, binge drinking
 

Drug Class

 

Amfetamine derivatives

Image (chem structure or protein)

Lisdexamfetamine structure rendering